Clarivate PLC (NYSE:CLVT - Get Free Report) insider Bar Veinstein sold 254,558 shares of Clarivate stock in a transaction that occurred on Wednesday, November 18th. The stock was sold at an average price of $2.13, for a total value of $542,208.54. Following the completion of the sale, the insider directly owned 1,008,458 shares in the company, valued at approximately $2,148,015.54. The trade was a 20.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Clarivate Price Performance
Shares of CLVT traded down $0.04 during mid-day trading on Friday, hitting $2.01. 5,696,820 shares of the stock were exchanged, compared to its average volume of 5,910,554. The company has a market cap of $1.29 billion, a PE ratio of -3.30 and a beta of 1.38. Clarivate PLC has a 52-week low of $1.42 and a 52-week high of $3.87. The firm has a 50-day moving average of $1.87 and a two-hundred day moving average of $2.18. The company has a debt-to-equity ratio of 0.92, a quick ratio of 0.88 and a current ratio of 0.88.
Clarivate (NYSE:CLVT - Get Free Report) last posted its earnings results on Wednesday, November 4th. The company reported $0.21 earnings per share for the quarter, beating analysts' consensus estimates of $0.18 by $0.03. Clarivate had a negative net margin of 17.02% and a positive return on equity of 9.84%. The firm had revenue of $481.60 million during the quarter, compared to analyst estimates of $566.77 million. During the same period last year, the firm posted $0.18 earnings per share. Clarivate's revenue for the quarter was down 22.7% compared to the same quarter last year. On average, equities analysts predict that Clarivate PLC will post 0.67 earnings per share for the current year.
Analysts Set New Price Targets
A number of equities analysts have commented on the stock. Jefferies Financial Group reissued a "hold" rating and issued a $2.25 price objective on shares of Clarivate in a research note on Thursday, November 5th. The Goldman Sachs Group lowered their price target on shares of Clarivate from $2.60 to $2.30 and set a "neutral" rating for the company in a report on Thursday, November 5th. Wall Street Zen lowered Clarivate from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. Citigroup dropped their price target on Clarivate from $2.80 to $2.50 and set a "neutral" rating for the company in a research report on Thursday, July 30th. Finally, Morgan Stanley began coverage on Clarivate in a research note on Friday, October 30th. They set an "underweight" rating and a $1.50 price objective on the stock. One research analyst has rated the stock with a Buy rating, five have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Reduce" and a consensus target price of $2.65.
Get Our Latest Report on Clarivate
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. American Century Companies Inc. lifted its holdings in shares of Clarivate by 30.2% in the 3rd quarter. American Century Companies Inc. now owns 18,566,836 shares of the company's stock worth $31,007,000 after acquiring an additional 4,301,119 shares during the last quarter. Goldman Sachs Group Inc. raised its position in Clarivate by 379.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 4,625,784 shares of the company's stock worth $7,725,000 after purchasing an additional 3,659,973 shares during the period. KBC Group NV bought a new stake in Clarivate in the first quarter worth about $4,118,000. Empowered Funds LLC boosted its position in shares of Clarivate by 418.6% during the first quarter. Empowered Funds LLC now owns 2,015,829 shares of the company's stock valued at $5,100,000 after buying an additional 1,627,159 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Clarivate during the first quarter valued at approximately $3,342,000. Institutional investors own 85.72% of the company's stock.
About Clarivate
(
Get Free Report)
Clarivate provides information, analytics and workflow tools to customers in academia and government, life sciences and healthcare, and intellectual property. Its services help organizations find and analyze research, assess scientific and commercial developments, and manage patents, trademarks and other intellectual property. Its products include Web of Science and ProQuest research resources, Cortellis life sciences intelligence, and intellectual property databases and services such as Derwent.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Clarivate, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clarivate wasn't on the list.
While Clarivate currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.